ASX Linkedin Twitter               

Dr Leonard Post
Non-Executive Director

Dr Post has extensive experience in oncolytic viruses, oncology and virotherapy. He was Senior Vice President of R&D at Onyx Pharmaceuticals and was responsible for the co-development (50:50 with Bayer) of Nexavar (sorafenib), from IND through FDA approval for renal cell carcinoma. Dr Post was a founder of US-based LEAD Therapeutics in 2007 which was subsequently acquired by BioMarin Pharmaceuticals in 2010. Dr Post served as the Chief Scientific Officer of BioMarin Pharmaceuticals until 2016.

Previously, as VP of Discovery Research at Parke-Davis, he led a multi-national drug discovery organisation of over 800 people, in cancer, infectious diseases, inflammation, cardiovascular and CNS. Prior to that, he held several positions at the Upjohn Company, including Director of Infectious Disease Research. During his industry career spanning more than 25 years, he has led numerous programs that have resulted in multiple clinical candidates across various therapeutic areas.

Dr Post was a Director of and consultant to Biovex Ltd, acquired by Amgen Inc in 2011. He is Chief Scientific Officer and Director of Vivace Therapeutics. He is a Director of three other North American biotechnology companies and has been a member of a number of Scientific Advisory Boards. Dr Post is also advisor to an Australian based venture capital firm. Dr Post has a PhD in Biochemistry, University of Wisconsin, Madison.

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).